Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial

Del Prete, Michela, Buteau, François-Alexandre, Arsenault, Frédéric, Saighi, Nassim, Bouchard, Louis-Olivier, Beaulieu, Alexis, Beauregard, Jean-Mathieu · 2019 · European Journal of Nuclear Medicine and Molecular Imaging

Abstract

Purpose Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of patients. We conceived a personalized PRRT protocol in which the IA is adjusted to deliver a prescribed absorbed dose to the kidney, with the aim to safely increase tumour irradiation. We herein report on the initial results of our prospective study of personalized PRRT, the P-PRRT Trial (NCT02754297). Methods PRRT-naïve patients with progressive and/or symptomatic neuroendocrine tumour (NET) were scheduled to receive a four-cycle induction course of 177 Lu-octreotate with quantitative SPECT/CT-based dosimetry. The IA was personalized according to the glomerular filtration rate and the body surface area for the first cycle, and according to the prior renal Gy/GBq for the subsequent cycles. The prescribed renal absorbed dose of 23 Gy was reduced by 25-50% in case of significant renal or haematological impairment. Responders were allowed to receive consolidation or maintenance cycles, for each of which 6 Gy to the kidney were prescribed. We simulated the empiric PRRT regime by fixing the IA at 7.4 GBq per cycle, with the same percentage reductions as above. Radiological, molecular imaging, biochemical, and quality of life responses, as well as safety, were assessed. Results Fifty-two patients underwent 171 cycles. In 34 patients who co…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00259-018-4209-7

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

See all 184

Metadata

Authors
Del Prete, M., Buteau, F.-A., Arsenault, F., Saighi, N., Bouchard, L.-O., Beaulieu, A., & Beauregard, J.-M.
Affiliations
  • Université Laval (CA)
  • Centre hospitalier universitaire de Québec (CA)
Corresponding author
Beauregard, Jean-Mathieu
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2018-11-30
Volume
46
Issue
3
Pages
728-742
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W2902656640
Cited by
184
References
26
Citations by year
2026: 12 · 2025: 28 · 2024: 28 · 2023: 34 · 2022: 31 · 2021: 28 · 2020: 13 · 2019: 9 · 2018: 1
FWCI
9.96
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Canadian Institutes of Health Research (MOP-142233)
  • Fonds de Recherche du Québec - Santé
  • Ministère de l'éducation et de l’enseignement supérieur du Québec
Topics
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
peptide receptor radionuclide therapy, 177Lu-octreotate, personalized dosimetry, glomerular filtration rate, renal dysfunction, neuroendocrine tumors, SPECT/CT dosimetry, treatment response, quality of life, hematologic toxicity
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Intestinal Neoplasms, Male, Middle Aged, Pancreatic Neoplasms, Radiometry, Safety, Stomach Neoplasms, Receptors, Peptide, Neuroendocrine Tumors, Young Adult, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. https://app.cochat.ai/papers/10.1007/s00259-018-4209-7
The paper
Del Prete, M., Buteau, F.-A., Arsenault, F., Saighi, N., Bouchard, L.-O., Beaulieu, A., & Beauregard, J.-M. (2019). Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-018-4209-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.